1.
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
by Rajasingham, Radha, Dr
The Lancet infectious diseases, 2017, Vol.17 (8), p.873-881
2.
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression ana...
by Gupta, Ravindra K
The Lancet infectious diseases, 2018, Vol.18 (3), p.346-355
3.
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection
by Colby, Donn J
Nature medicine, 2018, Vol.24 (7), p.923-926
4.
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
by Bar-On, Yotam
Nature medicine, 2018, Vol.24 (11), p.1701-1707
5.
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis
by Müller, Monika, BA
The Lancet infectious diseases, 2010, Vol.10 (4), p.251-261
6.
Defining total-body AIDS-virus burden with implications for curative strategies
by Estes, Jacob D
Nature medicine, 2017, Vol.23 (11), p.1271-1276
7.
Fungal infections in HIV/AIDS
by Limper, Andrew H
The Lancet infectious diseases, 2017, Vol.17 (11), p.e334-e343
8.
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
by Townsend, Claire L
AIDS (London), 2014, Vol.28 (7), p.1049-1057
9.
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomi...
by Cotton, Mark F, Prof
The Lancet (British edition), 2013, Vol.382 (9904), p.1555-1563
10.
Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study
by Hermans, Lucas E
The Lancet infectious diseases, 2018, Vol.18 (2), p.188-197
11.
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
by Fellay, Jacques
The Lancet (British edition), 2002, Vol.359 (9300), p.30-36
12.
Short Communication:Outcomes of Dual Versus Triple Antiretroviral Drug Regimens Among Virally Suppressed Adults in the DC Cohort
by Koay, Wei Li Adeline
AIDS research and human retroviruses, 2022, Vol.38 (6), p.451-454
13.
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study
by Hamers, Raph L, Dr
The Lancet infectious diseases, 2011, Vol.11 (10), p.750-759
14.
Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study
by Jani, Ilesh V, Dr
The Lancet (British edition), 2011, Vol.378 (9802), p.1572-1579
15.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, random...
by Cohen, Calvin J, Dr
The Lancet (British edition), 2011, Vol.378 (9787), p.229-237
16.
The end of AIDS: HIV infection as a chronic disease
by Deeks, Steven G, Prof
The Lancet (British edition), 2013, Vol.382 (9903), p.1525-1533
17.
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound
by Okoye, Afam A
Nature medicine, 2018, Vol.24 (9), p.1430-1440
18.
Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review
by GOVINDASAMY, Darshini
AIDS (London), 2012, Vol.26 (16), p.2059-2067
19.
The Association of HIV-Related Stigma to HIV Medication Adherence: A Systematic Review and Synthesis of the Literature
by Sweeney, Shannon M
AIDS and behavior, 2015, Vol.20 (1), p.29-50
20.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 tria...
by Choopanya, Kachit, MD
The Lancet (British edition), 2013, Vol.381 (9883), p.2083-2090
